-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec content team editor enGene announced today that EG-70, an innovative non-viral gene therapy for local administration in mucosal tissue based on its proprietary technology platform, is used in the treatment of high-grade non-muscle infiltrates unresponsive to Bacille Calmette-Guerin (BCG) Positive results from a phase 1/2 clinical trial in patients with meningococcal bladder cancer (NMIBC)
.
For more than 30 years, BCG immunotherapy has been the standard of care for NMIBC
.
However, the 60% rate of disease recurrence and progression after BCG therapy suggests that patients with NMIBC still have an urgent unmet medical need
.
Ultimately, most NMIBC patients who do not respond to BCG will undergo cystectomy, which removes the bladder at the same time as other surrounding organs
.
enGene's DDX platform utilizes chitosan derivatives to deliver DNA or RNA into mucosal tissues
.
EG-70 is a novel non-viral gene therapy that utilizes plasmids encoding two RIG-I agonists to stimulate the innate immune system, and IL-12 to stimulate the adaptive immune system
.
By stimulating both branches of the immune system, intravesical administration of EG-70 produced significant tumor regression in a preclinical model of bladder cancer and induced potent immune memory
.
Image source: 123RF clinical trial results show that EG-70 is safe and well tolerated, with encouraging clinical efficacy in patients with high-grade NMIBC in situ carcinoma who have failed BCG
.
Of the 6 patients evaluable for efficacy at 3 months, 5 achieved complete remission (CR)
.
This marks an 83% completion rate
.
"The response observed with EG-70 is an important step toward the goal of avoiding cystectomy in NMIBC patients,
"
said the clinical trial's principal investigator, Dr.
Gary Steinberg of NYU.
"If follow-up studies observe similar results, I believe this innovative intravesical monotherapy will have a meaningful impact on the lives of high-risk NMIBC patients
.
” Reference: [1] enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non- Muscle Invasive Bladder Cancer.
Retrieved February 8, 2022, from https:// unresponsive-non-muscle-invasive-bladder-cancer-301477766.
htmlDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
.
For more than 30 years, BCG immunotherapy has been the standard of care for NMIBC
.
However, the 60% rate of disease recurrence and progression after BCG therapy suggests that patients with NMIBC still have an urgent unmet medical need
.
Ultimately, most NMIBC patients who do not respond to BCG will undergo cystectomy, which removes the bladder at the same time as other surrounding organs
.
enGene's DDX platform utilizes chitosan derivatives to deliver DNA or RNA into mucosal tissues
.
EG-70 is a novel non-viral gene therapy that utilizes plasmids encoding two RIG-I agonists to stimulate the innate immune system, and IL-12 to stimulate the adaptive immune system
.
By stimulating both branches of the immune system, intravesical administration of EG-70 produced significant tumor regression in a preclinical model of bladder cancer and induced potent immune memory
.
Image source: 123RF clinical trial results show that EG-70 is safe and well tolerated, with encouraging clinical efficacy in patients with high-grade NMIBC in situ carcinoma who have failed BCG
.
Of the 6 patients evaluable for efficacy at 3 months, 5 achieved complete remission (CR)
.
This marks an 83% completion rate
.
"The response observed with EG-70 is an important step toward the goal of avoiding cystectomy in NMIBC patients,
"
said the clinical trial's principal investigator, Dr.
Gary Steinberg of NYU.
"If follow-up studies observe similar results, I believe this innovative intravesical monotherapy will have a meaningful impact on the lives of high-risk NMIBC patients
.
” Reference: [1] enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non- Muscle Invasive Bladder Cancer.
Retrieved February 8, 2022, from https:// unresponsive-non-muscle-invasive-bladder-cancer-301477766.
htmlDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
